Summit Therapeutics PLC (LON:SMMT)(NASDAQ:SUMM) has presented trial data at a US drug conference showing how its new series of antibiotics has high potency against drug-resistant antibiotics on the market.
The drug developer said it had presented in vivo (within living organisms) proof of concept data for its antibiotics targeting Enterobacteriaceae, a type of bacteria, in animal models of sepsis, pneumonia and urinary tract infection (UTI).
The DDS-04 series of series of antibiotics has the promise of combatting Enterobacteriaceae infections that cause more than one million infections annually in the US alone, the company estimated.
Summit added that the efficacy data showed the DDS-04 series were comparable to marketed antibiotics in all three disease models, and built on previous in vitro (outside a living organism) studies demonstrating that the new antibiotic class had “high potency” and targeted multiple resistant and non-resistant Enterobacteriaceae strains.
“Currently marketed broad-spectrum antibiotics for Enterobacteriaceae infections are failing patients at an increasingly alarming rate due to rising antibiotic resistance,” said David Roblin, Summit’s president of research & development, in a poster presentation at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance on Thursday.
He said the DDS-04 series works via a “new mechanism which has the potential to successfully cure patients by overcoming all known bacterial resistance mechanisms”.
The mechanism involves targeted compounds that act via a novel bacterial target that has been shown to be rapidly bactericidal and highly potent across diverse Enterobacteriaceae strains.
In early afternoon trading on Thursday, Summit shares were steady at 20p.